Update
$Annexon(ANNX.US$ Reuters· 5 mins ago
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
